MINI REVIEW

Pharmacoeconomics In India: The Need for Cost-Effectiveness in Drug Therapy

Akash Jain

Department of Pharmacology,
M.M. College of Pharmacy,
MM (DU), Mullana,
Ambala, Haryana, India.

Correspondence:
Dr. Akash Jain,
Professor,
Department of Pharmacology,
M.M. College of Pharmacy,
MM (DU), Mullana- 133207,
Ambala, Haryana, India.
E-Mail:akash.jain@mmumullana.org

How to cite this article: Jain K. Pharmacoeconomics in India: The Need for Cost-Effectiveness in Drug Therapy Innov Pharm Planet (IP-Planet) 2016;04(3)5-8.

Source of Support: Nil.
Conflicts of Interest: None declared.

Date of Submission: 11-07-2016
Date of Revision: 20-08-2016
Date of Acceptance: 24-08-2016

ABSTRACT:

Pharmacoeconomics plays a crucial role in optimizing healthcare expenditures while ensuring effective drug therapy, particularly in resource-limited settings like India. With the rising burden of chronic diseases and increasing drug costs, the need for cost-effectiveness in pharmacotherapy has become more significant. This review explores the principles of pharmacoeconomic, including cost-effectiveness analysis, cost-benefit analysis, and cost-utility analysis, and their relevance in the Indian healthcare system. The disparities between public and private healthcare, the impact of branded versus generic drugs, and the role of government policies such as the Drug Price Control Order (DPCO) are discussed in detail. Despite efforts to regulate drug pricing, challenges such as limited pharmacoeconomic research, lack of standardized health data, and physician and patient resistance hinder the effective implementation of cost-effective prescribing. Recent advancements, including Health Technology Assessment (HTA) and digital tools, offer promising solutions to enhance cost-efficiency in drug therapy. Strengthening pharmacoeconomic policies and promoting awareness among stakeholders is crucial for ensuring equitable access to affordable and effective medications in India. This review highlights the urgent need for integrating pharmacoeconomic principles into healthcare decision-making to improve patient outcomes while optimizing resource allocation.

KEYWORDS: Pharmacoeconomics, cost-effectiveness, drug pricing, healthcare policy, generic drugs, India.

INTRODUCTION

Pharmacoeconomics is a scientific discipline that focuses on evaluating the cost and value of pharmaceutical drugs and therapies. It combines principles from pharmacology, health economics, and outcomes research to assess the economic impact of drug interventions, comparing their costs and outcomes to guide decision-making and optimize resource allocation in healthcare systems. This field was first coined in 1986 and has since become crucial in analyzing the economic relationships throughout the development, marketing, and sale of pharmaceuticals. The significance of cost-effectiveness in healthcare, particularly in countries like India, cannot be overstated. With rising healthcare costs and limited resources, evaluating the cost-effectiveness of drug therapies is essential for ensuring that healthcare spending yields the best possible outcomes.

In India, where healthcare resources are often constrained, pharmacoeconomic analyses help policymakers allocate resources efficiently, ensuring that treatments provide the greatest health benefits for the investment made. This is particularly important in the context of universal health coverage initiatives, where cost-effectiveness analysis plays a key role in decision-making.

The objective of this review is to examine the role of pharmacoeconomic in optimizing healthcare costs while ensuring therapeutic efficacy. By analyzing the economic implications of pharmaceutical interventions, this discipline helps decision-makers navigate the complex landscape of healthcare resource allocation. The review aims to highlight how pharmacoeconomic supports value-based healthcare by identifying interventions that offer the greatest health benefits for the investment made, thereby informing reimbursement decisions, pricing negotiations, and formulary management[1].

OVERVIEW OF PHARMACOECONOMICS

Pharmacoeconomics evaluates the economic impact of healthcare interventions by balancing costs and outcomes to optimize resource allocation. This field employs various analytical methods to compare drug therapies and guide decision-making in healthcare systems.

Access this article online	
Website: https://innovationaljournals.com/index.php/ip	**e-ISSN:** 2348-7275

Key Concepts

Cost-Effectiveness Analysis (CEA)

CEA compares interventions based on costs per unit of health outcome (e.g., life years gained or cases prevented). It is used when therapies differ in efficacy but target the same condition. For example, a CEA might assess whether a new cancer drug justifies its higher cost by quantifying its survival benefits relative to existing treatments.

Cost-Utility Analysis (CUA)

CUA measures outcomes in quality-adjusted life years (QALYs), combining both survival duration and health-related quality of life. This method is ideal for comparing interventions across diseases or populations. A CUA could evaluate a diabetes medication's value by weighing its cost against improvements in mobility and reduced complications.

Cost-Benefit Analysis (CBA)

CBA converts all health outcomes into monetary terms, enabling direct comparison of costs and benefits. For instance, a CBA might calculate whether a vaccination program's societal savings (e.g., reduced hospitalizations) outweigh its implementation costs.

Cost-Minimization Analysis (CMA)

CMA is used when therapies have equivalent efficacy but differ in cost. It identifies the least expensive option, such as comparing generic and brand-name drugs with identical clinical outcomes[2].

Pharmacoeconomic Models

Decision-Tree Analysis

This model maps potential outcomes of interventions through branching pathways, incorporating probabilities and costs at each decision node. It is suited for short-term evaluations with discrete events (e.g., treating an infection with antibiotics vs. no treatment). Decision trees simplify complex scenarios but struggle with long-term or recurring events.

Markov Models

Markov models simulate chronic or recurrent conditions by dividing time into cycles and tracking transitions between health states (e.g., remission, relapse, death). They are ideal for long-term evaluations, such as comparing lifetime costs and outcomes of hypertension treatments. These models account for changing risks over time but require robust data on transition probabilities.

Pharmacoeconomic analyses are critical for informing drug pricing, reimbursement policies, and treatment guidelines, ensuring optimal healthcare resource allocation[3].

THE HEALTHCARE LANDSCAPE IN INDIA

Public vs. Private Healthcare Systems

India's healthcare system is bifurcated into public and private sectors, each with distinct affordability and accessibility challenges:

Public-private partnerships (PPPs) have emerged as a solution, leveraging private expertise (58% of hospitals, 81% of doctors) with public last-mile infrastructure (sub-centers, primary health clinics). For example, telemedicine initiatives like Sanjeevani bridge urban-rural gaps via technology[4].

Burden of High Drug Costs

High medication expenses strain Indian households:

Out-of-pocket spending pushes 55 million Indians into poverty annually.

Drug development costs and import reliance (e.g., APIs) inflate prices.

Price disparities: Essential drugs remain unaffordable despite regulations, with healthcare inflation at 6.6% in 2024.

Recent Budget 2025 initiatives aim to lower costs through:

Customs duty exemptions on life-saving drugs and cancer medications. Production-Linked Incentive (PLI) schemes for domestic pharmaceutical manufacturing. Subsidies for APIs and biosimilars to reduce dependency on imports.

Role of Government Policies

Drug Price Control Order (DPCO)

Regulates prices of 870+ essential drugs under the Essential Commodities Act.

Managed by the National Pharmaceutical Pricing Authority (NPPA), which capped prices for 42 formulations in February 2025. Challenges include balancing affordability with industry profitability and enforcing compliance.

Budgetary Initiatives

₹95,957.87 crore allocation for healthcare in 2025–26, focusing on cancer care (200 district centers), medical education (10,000 new seats), and rural connectivity.

Ayushman Bharat PM-JAY expansion to improve insurance coverage for 500 million vulnerable Indians.

Public-Pr Partnerships (PPPs)

Streamlined approvals and ₹7.7 billion investments in 2021 for healthcare PPPs.
Focus on telemedicine, rural infrastructure, and affordable care models.
These policies aim to reduce disparities, but gaps persist in rural access, workforce distribution, and equitable pricing[5].

COST-EFFECTIVENESS IN DRUG THERAPY

Essential vs. Non-Essential Medicines

Cost-effectiveness analysis (CEA) is central to determining drug inclusion in the WHO Essential Medicines List (EML). The EML prioritizes drugs that offer the greatest therapeutic value per unit cost, focusing on safety, efficacy, and public health relevance. For example, antiretrovirals for HIV and insulin for diabetes are included despite high costs due to their life-saving impact. However, cost-effectiveness evaluations within therapeutic groups often face challenges:

Limited economic data: Only 6% of WHO applications (2002–2013) included complete cost-effectiveness analyses, complicating standardized comparisons.

Total treatment cost focus: The EML emphasizes evaluating the cost of total treatment rather than unit drug prices, ensuring affordability at the system level.
Despite these criteria, high-cost drugs like lung surfactants for neonatal care are included if they address critical health needs, reflecting the balance between cost and clinical value.

Generic vs. Branded Drugs

Generic drug policies significantly improve affordability but face implementation challenges:
In India, policies like the Drug Price Control Order (DPCO) cap prices but often reference branded generics, perpetuating high costs. While generics reduce direct drug expenses, studies show mixed outcomes:

Cost savings: FDA reports generic competition lowers prices by 30–80%.

Hidden costs: Generic antiepileptics correlate with 25.8% higher healthcare costs due to increased hospitalizations[6].

Pharmacoeconomics in Chronic Disease Management

Chronic disease therapies require long-term cost-effectiveness evaluations:

Diabetes: Hybrid closed-loop (HCL) insulin systems in Australia show an incremental cost-effectiveness ratio of AUD $32,789/QALY, deemed cost-effective below the AUD $50,000 threshold.

Telehealth interventions: Personalized telehealth for COPD/diabetes patients improves QALYs by 0.09 at AUD $714/patient, with 65% cost-effectiveness probability.

Cancer: High-cost targeted therapies face scrutiny, but EML inclusion depends on survival benefits relative to alternatives.
Pharmacoeconomic models like Markov simulations and QALY-based analyses guide reimbursement decisions, ensuring sustainable resource allocation for chronic conditions[7].

CHALLENGES IN IMPLEMENTING PHARMACOECONOMIC PRINCIPLES IN INDIA

Lack of Standardized Data and Research

India faces significant gaps in real-world evidence (RWE) and cost-effectiveness data due to:
Poor data infrastructure: Manual, inconsistent record-keeping in public hospitals leads to unreliable data on drug costs, therapies, and patient outcomes. For example, studies in Egypt and Jordan highlight similar challenges, where <20% of hospitals maintain digitized records.

Biased RWE studies: Pharma-sponsored studies often focus on affluent urban populations, creating selection bias and overestimating efficacy. Only 6% of WHO applications (2002–2013) included robust cost-effectiveness analyses.

Insufficient funding: Less than 2% of India's healthcare budget is allocated to pharmacoeconomic research, limiting large-scale studies.
Efforts to address these gaps include proposals for a national database managed by the Department of Health Research (DHR) and adopting ISPOR guidelines to standardize data collection.

Regulatory and Policy Constraints

Regulatory frameworks often hinder cost-effective drug access:

Inconsistent pricing policies: The Drug Price Control Order (DPCO) caps prices for 870+ drugs but references branded generics, which are 10–12x costlier than true generics. For instance, metformin generics cost ₹2.86/unit vs. branded versions at ₹24.83/unit.

Short-term policy shifts: Sudden reversals, like the 2014 withdrawal of price controls on 108 drugs, create market instability and reduce trust in regulatory bodies like the NPPA.

Weak formulary systems: Public hospitals lack standardized treatment protocols, leading to fragmented procurement and inflated costs.

Proposed solutions include expanding DPCO to prioritize generics and establishing a NICE-like agency under DHR for evidence-based policymaking.

Patient and Physician Perspectives

Resistance to cost-effective prescribing stems from:

Brand loyalty: 67% of Indian physicians prefer prescribing branded drugs due to perceived efficacy and incentives from pharma companies.

Patient distrust: Only 15% of Indians trust generics, driven by misconceptions about quality and efficacy.

Lack of awareness: Over 80% of healthcare professionals lack training in pharmacoeconomics leading to irrational prescribing practices.

For example, generic antiepileptics are linked to 25.8% higher hospitalization costs due to therapeutic failures, reinforcing skepticism. Campaigns like Jan Aushadhi aim to counter this by promoting quality-assured generics, but uptake remains low (covering <5% of the population)[8].

CONCLUSION

In conclusion, pharmacoeconomic is essential for optimizing drug therapy costs while ensuring effective patient care in India. The integration of cost-effectiveness analyses, generic drug promotion, and regulatory frameworks can enhance affordability and accessibility. Despite existing challenges, advancements such as Health Technology Assessment (HTA) and digital health solutions offer promising improvements. Strengthening policies, research, and awareness among stakeholders is crucial for sustainable and equitable healthcare.

REFERENCE

1. Bhowmik, D., Duraivel, S., Rajalakshmi, A. N., & Kumar, S. (2014). Pharmacoeconomics-A Review. Pharmacy, 69, 23672-23675.
2. Reeder, C. E. (1995). Overview of pharmacoeconomics and pharmaceutical outcomes evaluations. *American journal of health-system pharmacy*, *52*(suppl_4), S5-S8.
3. Dervieux, T., & Bala, M. V. (2006). Overview of the pharmacoeconomics of pharmacogenetics. Pharmacogenomics, 7(8), 1175-1184.
4. Doherty, J., Kamae, I., Lee, K. K., Li, H., Li, S. C., Liu, G. G., ... & Yang, B. M. (2004). What is next for pharmacoeconomics and outcomes research in Asia?. Value in Health, 7(2), 118-132.
5. Rajput, H., & Raikwar, M. A. Regulatory Authority and Government Policies. *The Center for Drug Evaluation and Research uses different requirements for the three main drug products*, *13*(4), 1.
6. Dao, T. D. (1985). Cost-benefit and cost-effectiveness analysis of drug therapy. *American Journal of Hospital Pharmacy*, *42*(4), 791-802.
7. Chang, K., & Nash, D. (1998). The role of pharmacoeconomic evaluations in disease management. *PharmacoEconomics*, *14*(1), 11-17.
8. Gupta, S., Periwal, S., Nandy, B. C., & Mahanti, B. An Overview of Challenges, Importance and Evaluation of Pharmaeconomics: Role of Pharmacist's in Health Care System.